We are currently recruiting subjects aged 18 to 65 years old with moderate-to-severe alopecia areata for a study that evaluates the safety, effectiveness, and tolerability of an investigational treatment called daxdilimab. Alopecia areata is an autoimmune disease resulting in hair loss that is usually in one or more coin-shaped patches on the face, scalp or other areas of the body that grows hair. It should be noted that subjects with the presence of traction alopecia would not be eligible for this study. This type of alopecia is caused by repeatedly pulling on your hair, often a result of hairstyles or poor nutrition (example, tight ponytails, braids, buns, use of chemicals or heat on the hair).

The study consists of an investigational treatment that will be administered subcutaneously (by injection under the skin) every 4 weeks, for 32 weeks. There is no placebo for this study and all participants will be receiving the treatment.

This study will last 1 year and will include up to 14 visits. There is a 12-week post-treatment follow-up period lasting from Week 32 to Week 48 as the final planned clinic visit.

Compensation for travel and expenses may be provided if deemed eligible.